UK / Pharma Industry Warns of Declining Competitiveness
The UK government has decided to go ahead with a much-debated increase in the revenue clawback rate —from 24.4 percent to 27.5 percent— for drugmakers subject to its Statutory Scheme…
Address: Core Technology Facility
48 Grafton Street
Manchester
M13 9XX
,United Kingdom
Tel: +44 (0) 161 276 7100
Renovo is a biopharmaceutical product company and a leader in the discovery and development of drugs to reduce scarring, improve wound healing and enhance tissue regeneration.
In a comprehensive programme of Phase I/II clinical trials Renovo’s lead drug, Juvista, has demonstrated statistically significant results in improving the appearance of scars in the skin, which alone represents a multi-million dollar market of unmet medical need.
Renovo aims to be first to market with a pharmaceutical drug in the US and Europe to prevent and reduce scarring. There are currently no approved pharmaceuticals available in the US or Europe for this purpose.
Renovo has an exceptional team of highly experienced and innovative scientists and clinicians. Based in Manchester, UK, at the heart of a thriving centre for pharmaceutical research, Renovo has built a portfolio of drugs that have reached phase 2 and phase 3 of clinical development, as well as a rich pipeline at all stages of pre-clinical R&D.
A high performance culture of innovation as well as scientific and clinical excellence has allowed Renovo to pursue pioneering programmes of drug discovery and development in the rapidly evolving fields of scar prevention, wound healing and tissue regeneration. Renovo has its own fully staffed Clinical Trials Unit and a productive development team focussed on wound and scar biology, pharmacology, genomics and proteomics.
Juvista (INN: Avotermin – an intradermal injectable solution of Transforming Growth Factor Beta 3 (TGFβ3)), Renovo’s lead drug for the improvement of scar appearance in the skin, has been studied in an extensive early phase development programme in the EU, involving around 1,600 subjects. Efficacy, safety and dose response has been evaluated in statistically powered trials in both normal volunteers and patients, and following scientific advice from EMEA, a phase III programme for the EU has been agreed and initiated. The first EU Phase 3 trial was unsuccessful. The project is under review.
Prevascar (an intradermal injectable solution of human recombinant Interleukin 10) previously reported a positive exploratory efficacy trial for the reduction of scarring in the skin. Following improvements in the manufacturing of Prevascar drug substance and product, and identification of a clinical cohort who are predicted (on the basis of a non-drug experimental surgery study) to benefit particularly well from Prevascar’s modulating effect on the wound inflammatory response, Renovo has commenced a new proof of concept clinical trial in skin excisions and excisions in African-ancestral group human volunteers and is due to report interim data in H1 2011.
Adaprev an injectable solution of Mannose-6-Phosphate (M-6-P)) is being developed by Renovo as a Class III medical device in the EU for the prevention of adhesions (scar tissue) between tendon and tendon sheath, and the improvement of tendon function in patients undergoing surgical repair of flexor tendons in the hand. The first randomised, double-blind, standard care controlled, clinical trial commenced in November 2009 and is due to report in H2 2011.
Juvidex (topical application of Mannose-6-Phosphate (M-6-P)) reported statistically significant improvements in pre-specified endpoints of skin appearance and acceleration of healing in a proof of concept clinical trial. Renovo intends to partner Juvidex as a cosmetic ingredient, and is actively seeking a suitable partner to ensure its rapid development and commercialisation.
The development towards the clinic of RN1005, a promising pre-clinical candidate pharmaceutical (discovered by Renovo), targeting the Wnt pathway for reduction of scarring and stimulation of tissue regeneration has been greatly assisted by financial grants from the Government’s Technology Strategy Board (TSB) and the Knowledge Transfer Partnership.
The UK government has decided to go ahead with a much-debated increase in the revenue clawback rate —from 24.4 percent to 27.5 percent— for drugmakers subject to its Statutory Scheme…
Dr Matt Linley, senior director for analytics and forecasting at predictive health analytics firm Airfinity, looks ahead to a potentially game-changing year in the fight against respiratory synctial virus (RSV),…
A roundup of the latest UK healthcare, pharma and biotech news including AbbVie and Lilly’s departure from the country’s voluntary medicines pricing agreement, Moderna’s expanded footprint, UK biotech’s 2022 funding…
What digital skills do pharma leaders need in order to drive transformation, deliver success at scale in the business, and prepare for next-gen customer engagement? Sarah Gilchriest explores the critical…
Bernard Ross, a serial entrepreneur with more than 20 years’ senior experience at private and public board level across multiple industries, looks ahead to 2023 and highlights five key trends…
After an almost 20-year career in Big Pharma culminating in a role as president of AstraZeneca UK, Lisa Anson took the leap into the biotech world to lead what at…
Pricing and market access have become increasingly hot topics in recent years, as healthcare systems across the world attempt to balance their own financial sustainability with securing the latest medical…
National Health Service (NHS) England CEO Amanda Pritchard has raised concerns about the state of British healthcare in recent weeks and months, proclaiming that the NHS is in a worse…
With the brief tenure of Liz Truss as Prime Minister already drawing to a close, the UK faces yet another new leader as the country attempts to extricate itself from…
“Life sciences are at the heart of my vision to build a country fit for the future,” tweeted new UK Prime Minister Liz Truss last month. Now installed as leader…
US biotech Moderna – producer of a messenger RNA (mRNA) COVID-19 vaccine that has found its way into 75 million arms in the US alone and generated USD 12 billion…
After several scandals that revealed longstanding deficiencies and a continual churn of executive staff, a recent independent review of leadership in the National Health Service (NHS) has uncovered a lack…
See our Cookie Privacy Policy Here